The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Adjuvant etoposide plus cisplatin (EP) for pathologic stage (PS) II nonseminomatous germ cell tumor (NSGCT).
 
Deaglan Joseph McHugh
No Relationships to Disclose
 
Samuel Funt
Stock and Other Ownership Interests - Kite, a Gilead company
 
Deborah Silber
No Relationships to Disclose
 
Andrea Knezevic
No Relationships to Disclose
 
Sujata Patil
No Relationships to Disclose
 
Devon O'Donnell
No Relationships to Disclose
 
Stephanie Tsai
No Relationships to Disclose
 
Victor E. Reuter
No Relationships to Disclose
 
Joel Sheinfeld
No Relationships to Disclose
 
Brett Stewart Carver
No Relationships to Disclose
 
Robert J. Motzer
Consulting or Advisory Role - Eisai; Exelixis; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst)
 
Dean F. Bajorin
Honoraria - Merck Sharp & Dohme
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Fidia Farmaceutici S. p. A.; Genentech; Lilly; Lilly; Merck; Novartis; Roche; Roche/Genentech; Urogen pharma
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); dendreon (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; Merck; Roche/Genentech
 
George J. Bosl
No Relationships to Disclose
 
Darren R. Feldman
Research Funding - Novartis; Seagen